Literature DB >> 17189672

Pharmacological and histopathological characterization of a hyperalgesia model induced by freeze lesion.

Achim Schmidtko1, Maria Burian, Kosta Altis, Katja Hardt, Carlo Angioni, Ronald Schmidt, Maurizio Podda, Gerd Geisslinger.   

Abstract

Induction of a freeze lesion in human skin is an experimental model of hyperalgesia that allows assessing the antihyperalgesic effects of traditional non-steroidal anti-inflammatory drugs (NSAIDs). We have investigated whether this model is also sensitive to selective cyclooxygenase (COX)-2 inhibitors and have characterized morphological substrates of the generated hyperalgesia in the skin. In eight healthy subjects, a freeze lesion was induced and mechanical pain thresholds (MPT) were tested for 5h following administration of the non-selective COX inhibitor diclofenac (75mg), the COX-2-selective inhibitor parecoxib (40mg) or placebo in a randomized, double-blind cross-over study. In five additional healthy subjects, biopsies were taken from normal skin and the area of freezing injury. Induction of the freeze lesion resulted in hyperalgesia expressed by a decrease of MPT after 24h. Diclofenac and parecoxib, but not placebo, statistically significantly elevated MPT. Histochemical and Western blot analyses of skin biopsies revealed a strong upregulation of COX-2, a slight decrease of COX-1 and activation of nuclear factor kappa B (NF-kappaB) in the area of the freezing injury. These findings indicate that the freeze lesion model is sensitive to NSAIDs including selective COX-2 inhibitors, and that NF-kappaB-dependent COX-2 upregulation contributes to the hyperalgesia in this model.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17189672     DOI: 10.1016/j.pain.2006.11.002

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  4 in total

Review 1.  Clinical pharmacology of analgesics assessed with human experimental pain models: bridging basic and clinical research.

Authors:  Bruno Georg Oertel; Jörn Lötsch
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

2.  Similar maximum systemic but not local cyclooxygenase-2 inhibition by 50 mg lumiracoxib and 90 mg etoricoxib: a randomized controlled trial in healthy subjects.

Authors:  Lisa Felden; Carmen Walter; Carlo Angioni; Yannick Schreiber; Nils von Hentig; Nerea Ferreiros; Gerd Geisslinger; Jörn Lötsch
Journal:  Pharm Res       Date:  2014-01-28       Impact factor: 4.200

Review 3.  A literature review on the pharmacological sensitivity of human evoked hyperalgesia pain models.

Authors:  Guido van Amerongen; Matthijs W de Boer; Geert Jan Groeneveld; Justin L Hay
Journal:  Br J Clin Pharmacol       Date:  2016-07-08       Impact factor: 4.335

4.  Toll-like receptor 2 is important for the T(H)1 response to cutaneous sensitization.

Authors:  Haoli Jin; Lalit Kumar; Clinton Mathias; David Zurakowski; Hans Oettgen; Leonid Gorelik; Raif Geha
Journal:  J Allergy Clin Immunol       Date:  2009-04       Impact factor: 10.793

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.